Ambrx Biopharma Inc.
AMAMNYSEHealthcare
$28.00
+$0.02(+0.07%)
Market Cap$1.8B
P/E Ratio—
52W High$28.15
52W Low$6.55
Ambrx Biopharma Inc. (AMAM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AMAM · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $7.40M | $7.46M | $13.67M | $10.31M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $7.40M | $7.46M | $13.67M | $10.31M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | ||||
| R&D Expenses | $53.31M | $54.81M | $20.43M | $26.38M |
| G&A Expenses | $20.33M | $17.07M | $6.35M | $6.40M |
| Total Operating Expenses | $74.14M | $71.88M | $26.79M | $32.78M |
| Operating Income | ($57.08M) | ($64.42M) | ($13.12M) | ($22.47M) |
| Operating Margin %(computed) | -771.16% | -864.17% | -95.93% | -217.94% |
| Interest Income | $0.37M | $0.00M | $0.03M | $0.20M |
| Interest Expense | $0.97M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($76.06M) | ($68.29M) | ($17.84M) | ($22.32M) |
| Income Tax Expense | $1.94M | $0.00M | $0.00M | ($0.00M) |
| Net Income | ($78.00M) | ($68.29M) | ($17.84M) | ($22.31M) |
| Net Margin %(computed) | — | -916.00% | -130.49% | -216.40% |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-2.02 | $-3.34 | $-0.47 | $-0.59 |
| Wtd Avg Shares | 38.61M | 20.45M | 37.67M | 37.67M |
| EBITDA | ($63.17M) | ($62.27M) | ($11.17M) | ($20.42M) |
| EBITDA Margin %(computed) | -853.42% | -835.28% | -81.72% | -198.03% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Ambrx Biopharma Inc. data
About Ambrx Biopharma Inc. (AMAM) Income Statement
Ambrx Biopharma Inc. (AMAM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, AMAM reported revenue of $0.01B, gross profit of $0.01B (gross margin 100.00%), and net income of ($0.08B) — a net profit margin of -1053.72%.
Frequently asked questions
AMAM · 4 questionsAmbrx Biopharma Inc. (AMAM) reported revenue of $0.01B for 2022, down 0.7% year-over-year.
AMAM revenueAMAM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09